Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the receipt of clinical trial approval for a new drug (SYH2072 tablets) in China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a regulatory announcement regarding business operations and product development that does not fall into a more specific category, it is classified as a general regulatory filing.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN, DAPAGLIFLOZIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug combination. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company operations and product development, it falls under the RNS (Regulatory Filings) category.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the receipt of clinical trial approval for a new drug (SYH2069 Injection) from the National Medical Products Administration. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding company operations and product development, it falls under the RNS (Regulatory Filings) category.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT - DARATUMUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the receipt of clinical trial approval for a specific drug (Daratumumab Injection) in China. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a regulatory announcement regarding business operations and product development that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2025-12-23 English
VOLUNTARY ANNOUNCEMENT - SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new drug (SYH2085). It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general regulatory announcement regarding company operations and product development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-12-19 English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 1% confidence The document is a formal list of the company's Board of Directors, their roles, and their committee memberships. This type of disclosure is standard corporate governance documentation regarding board composition and does not fit into specific financial reporting categories like 10-K or ER. Since it provides information about the board structure and governance, it falls under the Governance Information category.
2025-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.